China is one of the largest producers of pharmaceutical raw materials (PRMs), largely due to its low production cost advantage and large population. China accounts for roughly 90.0% of global vitamin C output, 70.0% of citric acid output and 90.0% of penicillin output.
Rising health concerns among Chinese people and strong global demand led to rapid industry growth in the past five years. Total revenue for the Pharmaceutical Raw Material Manufacturing industry in China is expected to be $71.32 billion in 2014, up 11.6% from 2013. Over the five years, revenue has been increasing steadily at an average annual rate of 15.9%.
The Pharmaceutical Raw Material Manufacturing industry in China manufactures active pharmaceutical ingredients for further preparation of finished pharmaceutical products. Typical products in the industry include bacteriophage, endocrine products, basic vitamins, sulfanilamide medicine, salicylate, glucose and alkaloids. This industry acts as a bridge between the upstream chemical industry and the downstream medical market.
The report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecast, growth rates and an analysis of the industry key players and their market shares.